Overview of available treatment and new drug action points in obesity pharmacology. Will GIP, glucagon, amylin replace GLP-1?
Prospects in Pharmaceutical Sciences · 06.05.2025 · 23 (2) · 42-49
DOI: 10.56782/pps.361 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prospects in Pharmaceutical Sciences, online erschienen am 06.05.2025. Verfasst von Barbara Szostak und 9 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nearly 50% of the world's population struggles with excess body weight. Elevated BMI contributed to about 5 million deaths from non-communicable diseases in 2019 and is a defined negative predictor of numerous diseases, mainly on the cardiovascular side. The purpose of this article is to characterize possible new drug breakthrough points for obesity therapy and also to describe already available approaches. Pubmed and clinical trials databes was searched using obesity, GLP-1, GIP, glucagon, amylin as the key words. To date, five drugs have been registered in the European Union for the treatment of obesity. Of these, Glucagon-like peptide-1 agonists administered by subcutaneous injection are the most effective. In order to further increase the effectiveness of overweight therapy, research is underway to combine different mechanisms of action in a single preparation. Promising directions are substances that activate receptors for glucagon and amylin, which may represent new points of action in the treatment of obesity. A preparation combining agonism of glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon receptors - retatrutide - showed a significant weight reduction effect of 24% over 48 weeks. However, further studies including comparative analyses are needed to reliably assess their efficacy and safety.
Zitieren
APA
Szostak, B., Kułaga, M., Kasprzak, A., Grzybek, M., Mazur-Lesińska, D., Wielgosz-Biała, S., Tyszkiewicz, K., Łozowski, B., Kasprzak, M., & Wilczyńska, B. (2025). Overview of available treatment and new drug action points in obesity pharmacology. Will GIP, glucagon, amylin replace GLP-1?. Prospects in Pharmaceutical Sciences, 23(2), 42-49. https://doi.org/10.56782/pps.361
Vancouver
Szostak B, Kułaga M, Kasprzak A, Grzybek M, Mazur-Lesińska D, Wielgosz-Biała S, et al. Overview of available treatment and new drug action points in obesity pharmacology. Will GIP, glucagon, amylin replace GLP-1?. Prospects in Pharmaceutical Sciences. 2025;23(2):42-49. doi:10.56782/pps.361
BibTeX
@article{Szostak2025,
author = {Szostak, Barbara and Kułaga, Monika and Kasprzak, Anna and Grzybek, Monika and Mazur-Lesińska, Diana and Wielgosz-Biała, Sylwia and Tyszkiewicz, Krzysztof and Łozowski, Borys and Kasprzak, Małgorzata and Wilczyńska, Barbara},
title = {Overview of available treatment and new drug action points in obesity pharmacology. Will GIP, glucagon, amylin replace GLP-1?},
journal = {Prospects in Pharmaceutical Sciences},
year = {2025},
volume = {23},
number = {2},
pages = {42--49},
doi = {10.56782/pps.361}
}
EUVIMED